Long acting beta
Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
... salmeterol or formoterol was significantly lower after 1 week of treatment than after the first dose of long-acting beta-agonist. If receptor occupancy was the only explana- tion for the reduction in ...
7
Indacaterol: a new once daily long-acting beta<sub>2</sub> adrenoceptor agonist
... many long-term efficacy outcomes and gather further safety and tolerability data in both asthma and ...indacaterol, long-acting beta agonist, asthma, ...
5
Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
... used alone. Further, initial data from a single study sug- gests LABA/LAMA combinations may provide superior bronchodilator efficacy compared with LABA/ICS, at least in moderate COPD [146]; however, this was a short-term ...
14
Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
... In our study, the proportion of concomitant LABA/ICS users increased from 52.0% to 57.6% between 2004 and 2008. The observed increase could be related to an in- creased prescribing of i.[r] ...
10
Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
... agents acting on the renin–angiotensin system (eg, angiotensin-converting enzyme inhibitors, angiotensin II agonists), antihemorrhagics, antianemic preparations, beta-blockers, cardiac therapies, calcium ...
12
Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
... Notes: Data are presented as mean ± sD unless otherwise indicated. There was no statistical difference in each factor between the two groups. V25, expiratory airflow rate at 25% vital capacity. V50/V25, ratio of the ...
7
Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β<sub>2</sub>-adrenoreceptor agonist (uLABA)
... The five studies demonstrated that inhaled AZD3199 was well tolerated, had a good safety profile, and was not associated with consistent or clinically relevant systemic adv[r] ...
10
Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies
... Nevertheless, there is still a lack of knowledge regard- ing LABAs’ safety with concomitant ICs use, with both theoretical arguments and limited empirical evidence that ICs may mitigate LABA-associated risks [14-16]. ...
12
Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
... (Indacaterol 150 and 300 μ g, olodaterol 10 μ g, and vilanterol 25 μ g are not commercially available in the USA.) The efficacy of these LABAs was evaluated using the following [r] ...
15
Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis
... and/or placebo. Searches were limited to English language. We excluded pharmacokinetic studies, proof of concept studies, and trials with a cross-over design. Two reviewers independently screened studies by title and ...
11
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
... An important difference among the studies included in the evidence base is whether concomitant use of noninvestiga- tional COPD treatments was permitted in the trials by design. Specifically, the olodaterol trials ...
12
Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
... or more of the prescribed drugs without their physician’s authorization, and 53% did not use the correct dosage, giv- ing an adherence rate of 47%. After the educational program, when patients attended the maintenance ...
8
Effects of corticosteroid plus long-acting beta2-agonist on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice
... agonists (LABAs) are used worldwide for the treat- ment of asthma and COPD. Clinical trials showed that the combination of ICSs with LABAs improves symptoms and lung function and reduces exacerba- tions in subjects with ...
8
Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease
... on long acting beta agonist (LABA) or combined inhalers of corticosteroids and LABA, were matched for age, sex, BMI, FEV 1 % and number of pack-years smoked into two groups, those receiving pulmonary ...
5
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
... that beta-receptors recover rapidly following downregulation [31] and the timing of challenges 36 hours after the last dose of long-acting beta-agonist may mean that the tolerance measured in ...
7
Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis
... placebo, long-acting beta-agonists (salmeterol, formot- erol), long-acting anticholinergics (tiotropium bromide), and inhaled corticosteroids (budesonide, fluticasone, flu- nisolide, or ...
14
Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
... Objective: The aim of this study was to evaluate the cost-effectiveness of the long-acting beta-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator indacaterol[r] ...
10
Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
... COPD. Long-acting inhaled bronchodilators are prescribed for the symptomatic relief at any stage of disease ...with long-acting bronchodilator monotherapy, international guidelines suggest the ...
10
<p>Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study</p>
... including long-acting beta-agonists and anticholinergics (alone or in combination), should be the basic pharmaco- logical therapy for all patients with ...
9
The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
... and in vivo [27,28]. For instance, Bourbeau and colleagues found that 3 months of therapy with salmeterol/flutica- sone combination attenuated lung inflammation, as char- acterized by a reduction in the number of CD8 ...
13